Investors

2016 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle Download Print
12/19/16Brainstorm Reports on Successful End of Phase 2 Meeting with FDA, Upcoming Phase 3 Trial and Planned Application for Hospital Exemption for NurOwn®Download PDFPrinter Friendly Version
12/15/1621st Century Cures Act Passed by U.S. Congress Provides an Accelerated Approval Pathway for Regenerative Medicine TherapiesDownload PDFPrinter Friendly Version
12/14/16In-Depth Analyses Presented at International Symposium on ALS/MND Suggest Strong Biological Effect for NurOwn®; Evidence of Halting of Disease ProgressionDownload PDFPrinter Friendly Version
12/06/16BrainStorm to Host Year End Call with Investors to Discuss Important Corporate DevelopmentsDownload PDFPrinter Friendly Version
12/05/16BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MNDDownload PDFPrinter Friendly Version
11/15/16BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial ResultsDownload PDFPrinter Friendly Version
10/31/16BrainStorm Granted United States Patent for its Stem Cell TechnologyDownload PDFPrinter Friendly Version
09/17/16BrainStorm CEO to Present at Two Investor Conferences in SeptemberDownload PDFPrinter Friendly Version
09/06/16BrainStorm CEO to Present at Two Investor Conferences in SeptemberDownload PDFPrinter Friendly Version
08/11/16BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate UpdateDownload PDFPrinter Friendly Version
07/18/16BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS)Download PDFPrinter Friendly Version
07/14/16BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18Download PDFPrinter Friendly Version
05/17/16BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in LondonDownload PDFPrinter Friendly Version
05/12/16BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief ScientistDownload PDFPrinter Friendly Version
05/10/16BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate UpdateDownload PDFPrinter Friendly Version
03/29/16Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual MeetingDownload PDFPrinter Friendly Version
03/10/16BrainStorm Announces Financial Results for 2015 and Provides Business UpdateDownload PDFPrinter Friendly Version
03/08/16BrainStorm to Present at Bio-Asia-International and ARM Investor Day ConferencesDownload PDFPrinter Friendly Version
01/11/16BrainStorm's NurOwn® for the Treatment of ALS Published in JAMA NeurologyDownload PDFPrinter Friendly Version
01/11/16BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn® Trial in ALS at Hadassah Medical CenterDownload PDFPrinter Friendly Version